Christine Shieh1, Natasha Jones2, Brigitte Vanle3,4, Margaret Au5, Alden Y Huang6, Ana P G Silva2, Hane Lee7, Emilie D Douine8, Maria G Otero9, Andrew Choi9, Katheryn Grand10, Ingrid P Taff11, Mauricio R Delgado12, M J Hajianpour13, Andrea Seeley14, Luis Rohena15,16, Hilary Vernon17, Karen W Gripp18, Samantha A Vergano19, Sonal Mahida20, Sakkubai Naidu21,22, Ana Berta Sousa23, Karen E Wain24, Thomas D Challman24, Geoffrey Beek25, Donald Basel26, Judith Ranells27, Rosemarie Smith28, Roman Yusupov29, Mary-Louise Freckmann30, Lisa Ohden31, Laura Davis-Keppen32, David Chitayat33,34, James J Dowling35, Richard Finkel36, Andrew Dauber37, Rebecca Spillmann38, Loren D M Pena39,40, Kay Metcalfe41, Miranda Splitt42, Katherine Lachlan43,44, Shane A McKee45, Jane Hurst46, David R Fitzpatrick47, Jenny E V Morton48,49,50, Helen Cox48,49,50, Sunita Venkateswaran51, Juan I Young52, Eric D Marsh53, Stanley F Nelson8, Julian A Martinez54, John M Graham55, Usha Kini56, Joel P Mackay2, Tyler Mark Pierson57,58,59. 1. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 2. School of Life and Environmental Sciences, University of Sydney, Sydney, NSW, Australia. 3. Department of Psychiatry & Behavioral Neurosciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 4. Medical College of Wisconsin-Central Wisconsin, Wausau, WI, USA. 5. Department of Pediatrics Cedars-Sinai Medical Center, Los Angeles, CA, USA. 6. Institute for Precision Health, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. 7. Department of Human Genetics and Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. 8. Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. 9. Board of Governor's Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 10. Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 11. Department of Neurology, Hofstra School of Medicine, Great Neck, NY, USA. 12. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital for Children, Dallas, TX, USA. 13. Department of Pediatrics, Division of Medical Genetics, East Tennessee State University, Quillen College of Medicine, Mountain Home, TN, USA. 14. Geisinger Medical Center, Danville, PA, USA. 15. Division of Genetics, Department of Pediatrics, Brooke Army Medical Center, Fort Sam Houston, TX, USA. 16. Department of Pediatrics, UT Health San Antonio, Long School of Medicine, San Antonio, TX, USA. 17. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Balitmore, MD, USA. 18. Division of Medical Genetics, Al DuPont Hospital for Children, Wilmington, DE, USA. 19. Division of Medical Genetics and Metabolism, Children's Hospital of The King's Daughters, Norfolk, VA, USA. 20. Department of Neurogenetics, Kennedy Krieger Institute, Baltimore, MD, USA. 21. Department of Neurology and Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA. 22. Hugo Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD, USA. 23. Serviço de Genética Médica, Hospital Santa Maria, CHULN, Lisboa, Portugal and Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisboa, Portugal. 24. Autism & Developmental Medicine Institute, Geisinger, Lewisburg, PA, USA. 25. Children's Hospitals and Clinics of Minnesota Department of Genetics, Minneapolis, MN, USA. 26. Department of Pediatrics, Division of Genetics; Children's Hospital of Wisconsin, Milwaukee, WI, USA. 27. Division of Genetics and Metabolism, Department of Pediatrics, University of South Florida, Tampa, FL, USA. 28. Department of Pediatrics, Division of Genetics, Maine Medical Center, Portland, ME, USA. 29. Division of Clinical Genetics, Joe DiMaggio Children's Hospital, Hollywood, FlL, USA. 30. Royal North Shore Hospital, St Leonards, NSW, Australia. 31. Department of Genetic Counseling, Sanford Children's Specialty Clinic, Sioux Falls, SD, USA. 32. Department of Pediatrics, Sanford School of Medicine of the University of South Dakota, Sioux Falls, SD, USA. 33. The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. 34. Division of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. 35. Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada. 36. Division of Pediatric Neurology, Department of Pediatrics, Nemours Children's Hospital, Orlando, FL, USA. 37. Division of Endocrinology, Children's National Health System, Washington, DC, USA. 38. Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, NC, USA. 39. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 40. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 41. Manchester Centre for Genomic Medicine, Manchester University NHS FT, Manchester, UK. 42. Institute of Genetic Medicine, Northern Genetics Service, Newcastle upon Tyne Hospitals Trust, Newcastle, UK. 43. Faculty of Medicine, University of Southampton, Southampton, UK. 44. Human Development and Health Division, Wessex Clinical Genetics Service, University Hospitals of Southampton NHS Trust, Southampton, UK. 45. Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, UK. 46. Department of Clinical Genetics, NE Thames Genetics Service, Great Ormond Street Hospital, London, UK. 47. Medical Research Council Human Genetics Unit, University of Edinburgh, Edinburgh, UK. 48. West Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham, UK. 49. Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham, UK. 50. Birmingham Women's Hospital, Edgbaston, Birmingham, UK. 51. Division of Neurology, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada. 52. John P Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA. 53. Division of Neurology, Children's Hospital of Philadelphia and Department of Neurology and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 54. Department of Human Genetics; Division of Medical Genetics, Department of Pediatrics; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 55. Department of Pediatrics, Medical Genetics, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 56. Oxford Centre for Genomic Medicine, Oxford University Hospital NHS Foundation Trust, Oxford, UK. 57. Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Tyler.Pierson@cshs.org. 58. Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Tyler.Pierson@cshs.org. 59. Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Tyler.Pierson@cshs.org.
Abstract
PURPOSE: Determination of genotypic/phenotypic features of GATAD2B-associated neurodevelopmental disorder (GAND). METHODS: Fifty GAND subjects were evaluated to determine consistent genotypic/phenotypic features. Immunoprecipitation assays utilizing in vitro transcription-translation products were used to evaluate GATAD2B missense variants' ability to interact with binding partners within the nucleosome remodeling and deacetylase (NuRD) complex. RESULTS: Subjects had clinical findings that included macrocephaly, hypotonia, intellectual disability, neonatal feeding issues, polyhydramnios, apraxia of speech, epilepsy, and bicuspid aortic valves. Forty-one novelGATAD2B variants were identified with multiple variant types (nonsense, truncating frameshift, splice-site variants, deletions, and missense). Seven subjects were identified with missense variants that localized within two conserved region domains (CR1 or CR2) of the GATAD2B protein. Immunoprecipitation assays revealed several of these missense variants disrupted GATAD2B interactions with its NuRD complex binding partners. CONCLUSIONS: A consistent GAND phenotype was caused by a range of genetic variants in GATAD2B that include loss-of-function and missense subtypes. Missense variants were present in conserved region domains that disrupted assembly of NuRD complex proteins. GAND's clinical phenotype had substantial clinical overlap with other disorders associated with the NuRD complex that involve CHD3 and CHD4, with clinical features of hypotonia, intellectual disability, cardiac defects, childhood apraxia of speech, and macrocephaly.
PURPOSE: Determination of genotypic/phenotypic features of GATAD2B-associated neurodevelopmental disorder (GAND). METHODS: Fifty GAND subjects were evaluated to determine consistent genotypic/phenotypic features. Immunoprecipitation assays utilizing in vitro transcription-translation products were used to evaluate GATAD2B missense variants' ability to interact with binding partners within the nucleosome remodeling and deacetylase (NuRD) complex. RESULTS: Subjects had clinical findings that included macrocephaly, hypotonia, intellectual disability, neonatal feeding issues, polyhydramnios, apraxia of speech, epilepsy, and bicuspid aortic valves. Forty-one novelGATAD2B variants were identified with multiple variant types (nonsense, truncating frameshift, splice-site variants, deletions, and missense). Seven subjects were identified with missense variants that localized within two conserved region domains (CR1 or CR2) of the GATAD2B protein. Immunoprecipitation assays revealed several of these missense variants disrupted GATAD2B interactions with its NuRD complex binding partners. CONCLUSIONS: A consistent GAND phenotype was caused by a range of genetic variants in GATAD2B that include loss-of-function and missense subtypes. Missense variants were present in conserved region domains that disrupted assembly of NuRD complex proteins. GAND's clinical phenotype had substantial clinical overlap with other disorders associated with the NuRD complex that involve CHD3 and CHD4, with clinical features of hypotonia, intellectual disability, cardiac defects, childhood apraxia of speech, and macrocephaly.
Entities:
Keywords:
GATAD2B; NuRD complex; apraxia of speech; chromatin remodeling; macrocephaly
Authors: Ulrike Hüffmeier; Cornelia Kraus; Miriam S Reuter; Steffen Uebe; Mary-Alice Abbott; Syed A Ahmed; Kristyn L Rawson; Eileen Barr; Hong Li; Ange-Line Bruel; Laurence Faivre; Frédéric Tran Mau-Them; Christina Botti; Susan Brooks; Kaitlyn Burns; D Isum Ward; Marina Dutra-Clarke; Julian A Martinez-Agosto; Hane Lee; Stanley F Nelson; Pia Zacher; Rami Abou Jamra; Chiara Klöckner; Julie McGaughran; Jürgen Kohlhase; Sarah Schuhmann; Ellen Moran; John Pappas; Annick Raas-Rothschild; Maria J Guillen Sacoto; Lindsay B Henderson; Timothy Blake Palculict; Sureni V Mullegama; Houda Zghal Elloumi; Adi Reich; Samantha A Schrier Vergano; Erica Wahl; André Reis; Christiane Zweier Journal: Orphanet J Rare Dis Date: 2021-03-18 Impact factor: 4.303
Authors: Van N Huynh; Sheng Wang; Xiaosen Ouyang; Willayat Y Wani; Michelle S Johnson; Balu K Chacko; Anil G Jegga; Wei-Jun Qian; John C Chatham; Victor M Darley-Usmar; Jianhua Zhang Journal: Front Aging Date: 2021-09-29